BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15791438)

  • 1. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.
    Krak NC; Boellaard R; Hoekstra OS; Twisk JW; Hoekstra CJ; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):294-301. PubMed ID: 15791438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
    Stahl A; Ott K; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.
    Boellaard R; Krak NC; Hoekstra OS; Lammertsma AA
    J Nucl Med; 2004 Sep; 45(9):1519-27. PubMed ID: 15347719
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
    Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
    J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Scheiderbauer J; Machulla HJ; Dittmann H; Vonthein R; Bares R
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):263-9. PubMed ID: 16270214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters.
    Westerterp M; Pruim J; Oyen W; Hoekstra O; Paans A; Visser E; van Lanschot J; Sloof G; Boellaard R
    Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):392-404. PubMed ID: 17033848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.
    de Jong WK; van der Heijden HF; Pruim J; Dalesio O; Oyen WJ; Groen HJ
    J Thorac Oncol; 2007 Nov; 2(11):1007-12. PubMed ID: 17975491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of the OS-EM algorithm and comparison with FBP for image reconstruction on a dual-head camera: a phantom and a clinical 18F-FDG study.
    Gutman F; Gardin I; Delahaye N; Rakotonirina H; Hitzel A; Manrique A; Le Guludec D; Véra P
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1510-9. PubMed ID: 14579091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.
    Devic S; Mohammed H; Tomic N; Aldelaijan S; De Blois F; Seuntjens J; Lehnert S; Faria S
    Br J Radiol; 2016 Jun; 89(1062):20150388. PubMed ID: 27007269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET.
    Visvikis D; Cheze-LeRest C; Costa DC; Bomanji J; Gacinovic S; Ell PJ
    Eur J Nucl Med; 2001 Sep; 28(9):1326-35. PubMed ID: 11585291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of iterative reconstruction (OSEM) versus filtered back-projection for the assessment of myocardial glucose uptake and myocardial perfusion using dynamic PET.
    Søndergaard HM; Madsen MM; Boisen K; Bøttcher M; Schmitz O; Nielsen TT; Bøtker HE; Hansen SB
    Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):320-9. PubMed ID: 17033850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.
    Etchebehere EC; Macapinlac HA; Gonen M; Humm K; Yeung HW; Akhurst T; Scher HI; Larson SM
    Q J Nucl Med; 2002 Jun; 46(2):122-30. PubMed ID: 12114875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining a radiotherapy target with positron emission tomography.
    Black QC; Grills IS; Kestin LL; Wong CY; Wong JW; Martinez AA; Yan D
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1272-82. PubMed ID: 15519800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
    Lasnon C; Salomon T; Desmonts C; Dô P; Oulkhouir Y; Madelaine J; Aide N
    Ann Nucl Med; 2017 Feb; 31(2):125-134. PubMed ID: 27812791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.